This week we’re going to look at a patent covering the use of certain cannabinoids in combination with antipsychotics for increased therapeutic benefit. The patent is co-owned by GW Pharmaceuticals (GWPH) and Otsuka Pharmaceutical Co. (TYO) and granted in many regions including Canada and the USA. The USA patent doesn’t expire until 2029. Japan’s relationship with cannabis is unusual; they have strict laws around the possession of cannabis but have a long history of using cannabis fibers, scientists working to discover how cannabinoids are made and discovering the mechanisms behind their production in the plant.
Starting with the abstract:
“The present invention relates to the use of one or more cannabinoids in combination with one or more antipsychotic medications for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the antipsychotic medication is an atypical antipsychotic medication.”
This is a GW Pharma patent not a Canopy patent so there is some data showing the effectiveness of various cannabinoids when used in combination with antipsychotics. They tested the effectiveness of CBD and THCV in combination with aripiprazole (schizophrenia medication) on the constitutive androstane receptors (CAR) response in rats. It’s important to note that the patent doesn’t define CAR, always define your acronyms, what I’ve defined here is the most likely candidate. Their results showed a significant reduction in the number of rats with an induced CAR when sub-effective and effective doses of aripiprazole was used in combination with THCV. They also showed that CBD and THCV reduced the number of rats experiencing ptosis and catalepsy as a side effect from higher doses of aripiprazole.
The patent covers several cannabinoids and antipsychotic medications not tested in the patent. The types of neurological conditions covered ranges from schizophrenia, bipolar disorder and paranoia to depression. In summary, this patent has broad application in uses and coverage of cannabinoids. The list of atypical antipsychotic medication is less broad compared to the total number of antipsychotic medications. While the data they provide is better than nothing, following up with human trials would be an important step to demonstrating efficacy.
The author does not have a position in GWPH or TYO
Ads Blocker Detected!!!
We have detected that you are using extensions to block ads. Please support us by disabling your ad blocker.